about
Principles of antibody-mediated TNF receptor activationThe role of CD95 and CD95 ligand in cancerCD95 maintains stem cell-like and non-classical EMT programs in primary human glioblastoma cellsEndothelial cell-derived CD95 ligand serves as a chemokine in induction of neutrophil slow rolling and adhesionDeath induced by CD95 or CD95 ligand elimination.Fas palmitoylation by the palmitoyl acyltransferase DHHC7 regulates Fas stability.Infiltration of circulating myeloid cells through CD95L contributes to neurodegeneration in miceCD95 and CD95L promote and protect cancer stem cellsTNFα sensitizes neuroblastoma cells to FasL-, cisplatin- and etoposide-induced cell death by NF-κB-mediated expression of Fas.CD95 promotes metastatic spread via Sck in pancreatic ductal adenocarcinoma.Cellular sensing and transport of metal ions: implications in micronutrient homeostasis.Fas expression is downregulated in gastric cancer.CD95 ligand induces senescence in mismatch repair-deficient human colon cancer via chronic caspase-mediated induction of DNA damage.Lipid rafts and raft-mediated supramolecular entities in the regulation of CD95 death receptor apoptotic signaling.Activation of proteinase-activated receptor 2 prevents apoptosis of lung cancer cells.The Wilms' tumor suppressor WT1 enhances CD95L expression and promotes activation-induced cell death in leukemic T cells.Ligand stimulation of CD95 induces activation of Plk3 followed by phosphorylation of caspase-8.DICE: A novel tumor surveillance mechanism-a new therapy for cancer?CD95/Fas, Non-Apoptotic Signaling Pathways, and Kinases.Virus Infection and Death Receptor-Mediated Apoptosis.Molecular insights into the transcriptional regulatory role of thyroid hormones in ovarian cancer.Neutralization of CD95 ligand protects the liver against ischemia-reperfusion injury and prevents acute liver failure.Cell death-based treatment of childhood cancer.Cold atmospheric plasma as a potential tool for multiple myeloma treatment.The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer
P2860
Q26796270-02DC631A-5A44-4978-A1B3-E7DDF279F9ECQ26995847-BA290580-6DE7-48B5-BD71-B9B4DE9BBEB9Q27329081-5052B608-AA8A-4E22-BC49-3ED7A96CC55DQ28821976-A8B6FB19-C6DB-496A-8702-832383ADD1C2Q30582837-B2C9C4F8-D258-4FE1-ACF0-424637E31538Q35167590-BAB0E6B9-832F-4ECA-A972-1CCF37133412Q35289164-5E20DF0C-A0B9-49BE-B63F-6E7E895D4A8DQ35562681-A51F4E37-ED4E-4DD5-8073-8A030A832D92Q35609210-8305426E-4008-4848-AE94-EFA59C4AB982Q36067765-9AAEB542-ACA6-4F53-B7D7-B33F533201A9Q36244852-6A53F01C-E185-4622-84B2-233E7FE5181EQ37720085-AAD8C8CB-B8F5-47CE-B888-C2F11A2AA45CQ37745587-A519B4F3-5B7A-4A88-96A1-C4AA4DFDB5F0Q38363543-506574EE-E9F1-445D-BE01-8DABCF8C5E71Q39077024-02B0CC0F-B279-45C6-83A0-35DBF6522648Q39129209-C2028367-3E8F-45B1-9513-4842EBA07068Q39668561-DCC4E3FE-144E-49E5-89A3-81F5E0847A78Q40464867-3F40DB54-1C22-42C3-95BF-94D146AE75CBQ42288391-D0383E41-CA09-44E8-B0EB-32A1E2DFBE8FQ45325588-1606C7D2-FA01-444B-920E-5F47795F10D6Q47824971-3952411B-4C63-4C3C-82B5-0BAF6EB684AFQ49646757-4361598F-5F00-4B5A-B4CA-D6DE16CAF9FBQ49679684-168B801C-04D6-4128-8088-38E5F8C7E662Q54964245-030A5F1D-BFC7-49CB-80E8-610D9FB19272Q57114285-EA217721-D80D-4D17-B292-D8B87ACFA752
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
CD95 in cancer: tool or target?
@en
type
label
CD95 in cancer: tool or target?
@en
prefLabel
CD95 in cancer: tool or target?
@en
P1476
CD95 in cancer: tool or target?
@en
P2093
Ana Martin-Villalba
Damian Wollny
P304
P356
10.1016/J.MOLMED.2013.03.002
P577
2013-03-27T00:00:00Z